Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.

Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M, Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA.

Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060-3. doi: 10.1016/j.ygyno.2020.01.018. [Epub ahead of print]

PMID:
31959492
2.

Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.

Kim SH, Da Cruz Paula A, Basili T, Dopeso H, Bi R, Pareja F, da Silva EM, Gularte-Mérida R, Sun Z, Fujisawa S, Smith CG, Ferrando L, Martins Sebastião AP, Bykov Y, Li A, Silveira C, Ashley CW, Stylianou A, Selenica P, Samore WR, Jungbluth AA, Zamarin D, Abu-Rustum NR, Helin K, Soslow RA, Reis-Filho JS, Oliva E, Weigelt B.

Nat Commun. 2020 Jan 2;11(1):44. doi: 10.1038/s41467-019-13806-x.

3.

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.

Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R.

Int J Gynecol Cancer. 2019 Dec 22. pii: ijgc-2019-001012. doi: 10.1136/ijgc-2019-001012. [Epub ahead of print]

PMID:
31871115
4.

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.

Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, Mueller JJ, Leitao MM Jr, Friedman CF, Makker V, Soslow RA, DeLair DF, Hyman DM, Zamarin D, Alektiar KM, Aghajanian CA, Abu-Rustum NR, Weigelt B, Cadoo KA.

Gynecol Oncol. 2020 Jan;156(1):194-202. doi: 10.1016/j.ygyno.2019.10.028. Epub 2019 Nov 19.

PMID:
31757464
5.

PD-1 Blockade in Advanced Adrenocortical Carcinoma.

Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL.

J Clin Oncol. 2020 Jan 1;38(1):71-80. doi: 10.1200/JCO.19.01586. Epub 2019 Oct 23.

PMID:
31644329
6.

Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?

Zamarin D.

Mol Ther. 2019 Nov 6;27(11):1874-1877. doi: 10.1016/j.ymthe.2019.09.022. Epub 2019 Oct 2. No abstract available.

PMID:
31586519
7.

Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.

Vijayakumar G, Zamarin D.

Methods Mol Biol. 2020;2058:133-154. doi: 10.1007/978-1-4939-9794-7_9.

PMID:
31486036
8.

Novel therapeutics: response and resistance in ovarian cancer.

Zamarin D.

Int J Gynecol Cancer. 2019 Aug;29(Suppl 2):s16-s21. doi: 10.1136/ijgc-2019-000456.

PMID:
31462544
9.

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.

Liu YL, Zhou Q, Iasonos A, Emengo VN, Friedman C, Konner JA, O'Cearbhaill RE, Aghajanian C, Zamarin D.

Gynecol Oncol. 2019 Oct;155(1):51-57. doi: 10.1016/j.ygyno.2019.08.006. Epub 2019 Aug 14.

PMID:
31421916
10.

TOX is a critical regulator of tumour-specific T cell differentiation.

Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A.

Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17.

PMID:
31207604
11.

Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.

Dyer BA, Zamarin D, Eskandar RN, Mayadev JM.

J Natl Compr Canc Netw. 2019 Jan;17(1):91-97. doi: 10.6004/jnccn.2018.7108. Review.

PMID:
30659133
12.

Virus, Vessel, Victory: A Novel Approach to Tumor Killing.

Bykov Y, Zamarin D.

Clin Cancer Res. 2019 Mar 1;25(5):1446-1448. doi: 10.1158/1078-0432.CCR-18-3441. Epub 2018 Dec 10.

PMID:
30530816
13.

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D.

Gynecol Oncol. 2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025. Epub 2018 Nov 22.

14.

Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.

Liu YL, Zamarin D.

Curr Oncol Rep. 2018 Nov 13;20(12):94. doi: 10.1007/s11912-018-0740-8. Review.

15.

IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.

Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, Raundhal M, Chaurio RA, Payne KK, Konrad C, Bettigole SE, Shin HR, Crowley MJP, Cerliani JP, Kossenkov AV, Motorykin I, Zhang S, Manfredi G, Zamarin D, Holcomb K, Rodriguez PC, Rabinovich GA, Conejo-Garcia JR, Glimcher LH, Cubillos-Ruiz JR.

Nature. 2018 Oct;562(7727):423-428. doi: 10.1038/s41586-018-0597-x. Epub 2018 Oct 10.

16.

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD.

J Clin Invest. 2018 Nov 1;128(11):5184. doi: 10.1172/JCI125039. Epub 2018 Oct 2. No abstract available.

17.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.

18.

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.

Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D.

Oncotarget. 2018 Jun 19;9(47):28702-28716. doi: 10.18632/oncotarget.25614. eCollection 2018 Jun 19.

19.

Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study.

Oseledchyk A, Gennarelli RL, Leitao MM Jr, Aghajanian CA, Iasonos A, Zivanovic O, Zamarin D.

Cancer Med. 2018 Jun;7(6):2280-2287. doi: 10.1002/cam4.1447. Epub 2018 Apr 17.

20.

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD.

J Clin Invest. 2018 Apr 2;128(4):1413-1428. doi: 10.1172/JCI98047. Epub 2018 Mar 5. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5184.

21.

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.

Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D.

Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. Epub 2018 Jan 31.

22.

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.

Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, Zamarin D.

J Natl Cancer Inst. 2018 Jul 1;110(7):787-790. doi: 10.1093/jnci/djx277.

23.

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

Zamarin D.

Mol Ther. 2018 Jan 3;26(1):9-12. doi: 10.1016/j.ymthe.2017.12.006. Epub 2017 Dec 15. No abstract available.

24.

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.

Oseledchyk A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, Brown CL, Snyder A, Chi DS, Soslow RA, Abu-Rustum NR, Zivanovic O.

Ann Oncol. 2017 Dec 1;28(12):2985-2993. doi: 10.1093/annonc/mdx525.

25.

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok JD, Sala E, Merghoub T, Snyder A, Miller ML.

Cell. 2017 Aug 24;170(5):927-938.e20. doi: 10.1016/j.cell.2017.07.025.

26.

Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells.

Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca JM, Zamarin D, Shuman S, Merghoub T, Wolchok JD, Deng L.

Sci Immunol. 2017 May 19;2(11). pii: eaal1713. doi: 10.1126/sciimmunol.aal1713.

27.

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.

Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP.

Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340.

28.

Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors.

Ricca J, Turkekul M, Barlas A, Yarilin D, Fujisawa S, Fan N, Brendel M, Zamarin D, Wolchok JD, Manova-Todorova K.

Methods Mol Biol. 2017;1554:253-262. doi: 10.1007/978-1-4939-6759-9_18.

29.

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.

Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD.

EBioMedicine. 2016 Apr;6:50-58. doi: 10.1016/j.ebiom.2016.02.024. Epub 2016 Feb 13.

30.

Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Zamarin D, Jazaeri AA.

Gynecol Oncol. 2016 Apr;141(1):86-94. doi: 10.1016/j.ygyno.2015.12.030. Review.

31.

Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies.

Bourla AB, Zamarin D.

Oncology (Williston Park). 2016 Jan;30(1):59-66, 69. Review.

32.

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD.

Cell Rep. 2015 Oct 13;13(2):412-24. doi: 10.1016/j.celrep.2015.08.077. Epub 2015 Sep 24.

33.

Immunotherapy of Melanoma.

Snyder A, Zamarin D, Wolchok JD.

Prog Tumor Res. 2015;42:22-9. doi: 10.1159/000436998. Epub 2015 Sep 4. Review.

PMID:
26376963
34.

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T.

Adv Cancer Res. 2015;128:1-68. doi: 10.1016/bs.acr.2015.04.010. Epub 2015 Jun 9. Review.

PMID:
26216629
35.

Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data.

Zamarin D, Pesonen S.

Hum Gene Ther. 2015 Aug;26(8):538-49. doi: 10.1089/hum.2015.055. Review.

36.

Immune checkpoint modulation: rational design of combination strategies.

Zamarin D, Postow MA.

Pharmacol Ther. 2015 Jun;150:23-32. doi: 10.1016/j.pharmthera.2015.01.003. Epub 2015 Jan 10. Review.

PMID:
25583297
37.

Harnessing the immune system for cancer therapy.

Smith EL, Zamarin D, Lesokhin AM.

Curr Opin Oncol. 2014 Nov;26(6):600-7. doi: 10.1097/CCO.0000000000000128. Review.

PMID:
25250678
38.

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP.

Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.

39.

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.

Zamarin D, Wolchok JD.

Mol Ther Oncolytics. 2014 Dec 10;1:14004. doi: 10.1038/mto.2014.4. eCollection 2014. Review.

40.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.

J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. Epub 2013 Jun 10.

41.

Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.

Zamarin D, Devlin SM, Arcila ME, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Weltz J, Babu D, Giralt S, Hassoun H.

Leukemia. 2013 Dec;27(12):2422-4. doi: 10.1038/leu.2013.126. Epub 2013 Apr 23. No abstract available.

PMID:
23608883
42.

Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.

Zamarin D, Giralt S, Landau H, Lendvai N, Lesokhin A, Chung D, Koehne G, Chimento D, Devlin SM, Riedel E, Bhutani M, Babu D, Hassoun H.

Bone Marrow Transplant. 2013 Mar;48(3):419-24. doi: 10.1038/bmt.2012.151. Epub 2012 Aug 13.

43.

Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Zamarin D, Palese P.

Future Microbiol. 2012 Mar;7(3):347-67. doi: 10.2217/fmb.12.4. Review.

44.

Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.

Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ.

Head Neck. 2011 Oct;33(10):1394-9. doi: 10.1002/hed.21609. Epub 2010 Nov 4.

45.

The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.

Davtyan H, Ghochikyan A, Cadagan R, Zamarin D, Petrushina I, Movsesyan N, Martinez-Sobrido L, Albrecht RA, García-Sastre A, Agadjanyan MG.

J Transl Med. 2011 Aug 1;9:127. doi: 10.1186/1479-5876-9-127.

46.

Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.

Mansour M, Palese P, Zamarin D.

J Virol. 2011 Jun;85(12):6015-23. doi: 10.1128/JVI.01537-10. Epub 2011 Apr 6.

47.

Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.

Silberhumer GR, Brader P, Wong J, Serganova IS, Gönen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y.

Mol Cancer Ther. 2010 Oct;9(10):2761-9. doi: 10.1158/1535-7163.MCT-10-0090. Epub 2010 Sep 21.

48.

Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines.

Dai MH, Zamarin D, Gao SP, Chou TC, Gonzalez L, Lin SF, Fong Y.

Br J Surg. 2010 Sep;97(9):1385-94. doi: 10.1002/bjs.7124.

PMID:
20629009
49.

Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer.

Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y.

J Mol Med (Berl). 2010 Jun;88(6):589-96. doi: 10.1007/s00109-010-0605-6.

50.

Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus.

Wong J, Schulman A, Kelly K, Zamarin D, Palese P, Fong Y.

J Gastrointest Surg. 2010 Jan;14(1):7-14. doi: 10.1007/s11605-009-1071-8. Epub 2009 Nov 10.

Supplemental Content

Loading ...
Support Center